Athenex, Inc. (ATNX)
(Delayed Data from NSDQ)
$10.12 USD
+0.19 (1.91%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.09 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.12 USD
+0.19 (1.91%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.09 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
After Plunging 25.6% in 4 Weeks, Here's Why the Trend Might Reverse for Athenex (ATNX)
by Zacks Equity Research
Athenex (ATNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Athenex (ATNX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Athenex (ATNX) delivered earnings and revenue surprises of 19.51% and -0.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Athenex (ATNX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Athenex (ATNX) Skin Treatment Klisyri Gets Approval in Europe
by Zacks Equity Research
Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.
Omeros' (OMER) BLA for Narsoplimab Gets Extended Review
by Zacks Equity Research
The FDA extends review period for Omeros' (OMER) BLA seeking approval of narsoplimab for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. Stock down.
Agenus (AGEN) Soars on Global License Deal With Bristol-Myers
by Zacks Equity Research
Agenus (AGEN) inks a definitive agreement with Bristol-Myers, wherein it will grant license to its bispecific antibody program AGEN1777 and another undisclosed target, to the latter.
Bayer (BAYRY) Inks Deal to Develop Therapies for Eye Diseases
by Zacks Equity Research
Bayer (BAYRY) enters a strategic deal with FUJIFILM Cellular Dynamics and Opsis Therapeutics to discover and develop cell therapies for addressing eye diseases.
Athenex (ATNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Athenex (ATNX) delivered earnings and revenue surprises of 27.03% and 110.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Athenex (ATNX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Athenex (ATNX) delivered earnings and revenue surprises of -26.19% and 11.65%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Athenex (ATNX) Gets FDA Approval for Skin Treatment Klisyri
by Zacks Equity Research
Athenex (ATNX) wins the FDA nod for Klisyri as a topical treatment of actinic keratosis on the face or scalp. The drug will be launched in the first quarter of 2021 in the United States.
Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Athenex (ATNX) delivered earnings and revenue surprises of 4.35% and 81.93%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Athenex (ATNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Athenex (ATNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Athenex's NDA for Breast Cancer Drug Gets Priority Review
by Zacks Equity Research
The FDA accepts Athenex's (ATNX) NDA for oral paclitaxel and encequidar, intended to treat metastatic breast cancer, under a priority review. The FDA's verdict is awaited on Feb 28, 2021. Stock up.
Athenex (ATNX) Catches Eye: Stock Jumps 9.1%
by Zacks Equity Research
Athenex (ATNX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Athenex (ATNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Athenex (ATNX) delivered earnings and revenue surprises of -32.26% and 89.49%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Athenex (ATNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Athenex (ATNX) Rating Upgrade to Strong Buy
by Zacks Equity Research
Athenex (ATNX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Athenex (ATNX): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Athenex (ATNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Athenex (ATNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Athenex (ATNX) delivered earnings and revenue surprises of -14.29% and 46.90%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Athenex (ATNX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Athenex, Inc. (ATNX) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Athenex, Inc. (ATNX).
Athenex (ATNX) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Athenex (ATNX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Athenex (ATNX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Athenex (ATNX) delivered earnings and revenue surprises of 44.00% and 185.15%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Moving Average Crossover Alert: Athenex
by Zacks Equity Research
Athenex, Inc. (ATNX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Are Options Traders Betting on a Big Move in Athenex (ATNX) Stock?
by Zacks Equity Research
Investors need to pay close attention to Athenex (ATNX) stock based on the movements in the options market lately.